1 March 2019 New paper relevant for the optimal development of drugs targeting LSD1 published by ORYZON
15 February 2019 ORYZON Reports Financial Results and Corporate Update for the 4thQuarter and Year Ended December 31, 2018
6 February 2019 ORYZON Announces Publication of a relevant paper for the therapeutic development of Iadademstat (ORY-1001) in Small Cell Lung Cancer (SCLC)
7 January 2019 ORYZON appoints Michael T. Ropacki, PhD as Vice President of Clinical Development for its CNS epigenetic program
11 December 2018 ORYZON receives a new 1.14 M USD public grant to explore new indications for epigenetic inhibitors
3 December 2018 Oryzon announces First-Patients-in in CLEPSIDRA: a Phase IIa clinical trial with Iadademstat (ORY-1001) in Small Cell Lung Cancer patients
12 November 2018 Oryzon announces First-Patient-in in ALICE: a Phase IIa clinical trial with Iadademstat (ORY-1001) in Acute Myeloid Leukemia patients